DarioHealth Reports Q2 2026 Financial Results with Revenue Decline and Improved Operating Loss

DarioHealth Corp. reported its financial results for the second quarter of 2026, revealing total revenues of $5.2 million, a slight decrease from $5.4 million in the same period last year. For the first half of 2026, revenues totaled $10.8 million, down from $12.1 million in the first half of 2025. The company's service revenues fell to $2.6 million from $3.7 million year-over-year, while consumer hardware revenues increased to $2.6 million from $1.7 million. Despite the revenue decline, DarioHealth achieved a gross profit of $3.2 million for the quarter, compared to $3.0 million in Q2 2025.

The company experienced a significant increase in operating expenses, which totaled $9.7 million for the second quarter, down from $12.2 million in the prior year. This reduction was primarily due to lower research and development costs, which decreased to $2.1 million from $3.7 million, and a reduction in general and administrative expenses. However, the overall operating loss for the quarter was $6.5 million, an improvement from the $9.2 million loss reported in Q2 2025. The net loss attributable to common shareholders was $7.9 million, compared to $18.6 million in the same quarter last year.

DarioHealth's operational metrics indicate a strategic focus on enhancing its digital therapeutic offerings. The company has expanded its customer base through its B2B2C arrangements, generating $2.5 million in revenues from these contracts in Q2 2026, although this was a decrease from $3.5 million in Q2 2025. The company also reported an increase in consumer revenues, which rose to $2.7 million from $1.8 million year-over-year. As of June 30, 2026, DarioHealth had a total of 7.3 million shares outstanding, reflecting a recent reverse stock split.

In terms of financial health, DarioHealth's cash and cash equivalents decreased to $6.6 million from $21.8 million at the end of 2025. The company has an accumulated deficit of $468.3 million as of June 30, 2026, and reported cash used in operations of approximately $12.1 million for the first half of the year. DarioHealth has entered into securities purchase agreements that are expected to provide approximately $23.5 million in gross proceeds, which management believes will support operations for at least the next twelve months.

Looking ahead, DarioHealth anticipates continued challenges in achieving profitability, with future net losses expected as the company focuses on the development and commercialization of its digital therapeutic products. The company remains committed to enhancing its market presence and expanding its product offerings, which it views as critical to achieving sustainable revenue growth.